Jetema Co Ltd

Jetema maintains a debt-to-equity ratio of 1.67, indicating a capital structure that is moderately leveraged relative to equity. The company holds 31.0 billion KRW in cash and equivalents, but this is insufficient to cover its 116.99 billion KRW in long-term debt, resulting in a negative net cash position. The current ratio of 0.61 suggests liquidity constraints, as current liabilities exceed current assets. Free cash flow is minimal at 11.73 million KRW, far below the 2.325 billion KRW in operating cash flow, indicating significant capital expenditure requirements.

Profitability metrics show a return on equity of -2.00% and a return on assets of -0.62%, both well below the industry median for pharmaceutical firms. Gross profit of 9.34 billion KRW represents 54.2% of revenue, but operating income of 597.33 million KRW reflects high operating expenses. The company reported a net loss of 1.406 billion KRW, driven by R&D and SG&A costs that outpace revenue growth.

Geographically, Jetema's revenue is concentrated in South Korea, with no material international operations disclosed in the latest financials. The company operates in a single business segment focused on prescription pharmaceuticals, with no diversification into medical devices or biologics.

Revenue growth has been stagnant, with a 0.00% year-over-year change in the most recent period. Analysts project a 40.00% increase in revenue to 24.1 billion KRW in the next fiscal year, but this remains speculative given the company's current net loss position. The price-to-book ratio of 2.79 and EV/EBITDA of 471.88 suggest the stock is trading at a premium to tangible book value and earnings, despite negative net income.

Risk factors include a medium liquidity risk due to the negative net cash position and a debt load that exceeds cash reserves. Dilution risk is currently low, but the company has 36.008 million shares outstanding with no dilutive instruments disclosed. Recent filings show no material regulatory or litigation risks, but the company's reliance on a narrow product portfolio increases business risk.

Analyst coverage is limited, with one strong-buy recommendation and a mean price target of 9,000 KRW, implying a 65.5% upside from the current market price of 5,440 KRW. No recent earnings call transcripts or investor presentations were available to assess management commentary on strategic direction.

Analysts project 65.4% upside to a 9,000 KRW target price, rating the stock a strong buy.

Revenue grew 31.0% year-over-year to 76.9 billion KRW, demonstrating significant top-line expansion momentum.

Gross profit reached 36.8 billion KRW, indicating strong underlying profitability before operating expenses and interest costs.

Capex to revenue ratio of -2.17% is above the pharmaceutical cohort median, suggesting lower capital intensity.

Debt-to-equity ratio of 1.67 sits in the bottom quartile, indicating excessive leverage compared to peers.

The company faces high credit risk and medium liquidity risk, threatening financial stability and solvency.

Revenue KRW 20.38B, +7,1% YoY; Operating income +65,3% YoY.

• ▍Revenue KRW 20.38B, +7,1% YoY
• ▍Operating income +65,3% YoY
• ▍Net income −49,5% YoY
• ▍Free cash flow +177,9% YoY
• ▍Net margin 11.2%

Revenue KRW 15.83B, −8,1% YoY; Operating income −246,7% YoY.

• ▍Revenue KRW 15.83B, −8,1% YoY
• ▍Operating income −246,7% YoY
• ▍Net income −160,5% YoY
• ▍Free cash flow −49 141,1% YoY
• ▍Net margin -23.1%

Revenue KRW 19.03B; Operating income -KRW 1.11B.

• ▍Revenue KRW 19.03B
• ▍Operating income -KRW 1.11B
• ▍Net margin 23.8%

Revenue KRW 68.52B, +16,7% YoY; Operating income +84,1% YoY.

• ▍Revenue KRW 68.52B, +16,7% YoY
• ▍Operating income +84,1% YoY
• ▍Net income −101,3% YoY
• ▍Free cash flow −118,1% YoY
• ▍Net margin -0.3%